These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 15960423)

  • 1. Synthesis and evaluation of N-(5-methyl-3-oxo-1,2- diphenyl-2,3-dihydro-1H-pyrazol-4-yl)-N'-phenylureas as cholecystokinin antagonists.
    Lattmann E; Sattayasai J; Boonprakob Y; Lattmann P; Singh H
    Arzneimittelforschung; 2005; 55(5):251-8. PubMed ID: 15960423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of N-(3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-1H-indole-carboxamides as cholecystokinin antagonists.
    Lattmann E; Singh H; Boonprakob Y; Lattmann P; Sattayasai J
    J Pharm Pharmacol; 2006 Mar; 58(3):393-401. PubMed ID: 16536908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholecystokinin antagonists (part 1): Antinociceptive, anxiolytic and antidepressant effects of N-(5-methyl-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazol-4-yl)-N'-phenylureas and carboxamides.
    Lattmann E; Sattayasai J; Boonprakob Y; Singh H; Lattmann P; Dunn S
    Drug Discov Ther; 2008 Jun; 2(3):156-67. PubMed ID: 22504568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo evaluation of substituted 3-amino-1,4-benzodiazepines as anti-depressant, anxiolytic and anti-nociceptive agents.
    Lattmann E; Lattmann P; Boonprakob Y; Airarat W; Singh H; Offel M; Sattayasai J
    Arzneimittelforschung; 2009; 59(2):61-71. PubMed ID: 19338136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Part 2. Long term in vivo/in vitro evaluation of the Cholecystokinin antagonists: N-(5-methyl-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazol-4-yl)-N'-phenylurea MPP and carboxamide MPM.
    Lattmann E; Boonprakob Y; Sattayasai J
    Drug Discov Ther; 2008 Dec; 2(6):344-52. PubMed ID: 22504744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of substituted 3-anilino-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-ones and their evaluation as cholecystokinin-ligands.
    Offel M; Lattmann P; Singh H; Billington DC; Bunprakob Y; Sattayasai J; Lattmann E
    Arch Pharm (Weinheim); 2006 Apr; 339(4):163-73. PubMed ID: 16572480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
    Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
    J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.
    Zajdel P; Subra G; Bojarski AJ; Duszyńska B; Tatarczyńska E; Nikiforuk A; Chojnacka-Wójcik E; Pawłowski M; Martinez J
    Bioorg Med Chem; 2007 Apr; 15(8):2907-19. PubMed ID: 17321139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas.
    Castro JL; Ball RG; Broughton HB; Russell MG; Rathbone D; Watt AP; Baker R; Chapman KL; Fletcher AE; Patel S; Smith AJ; Marshall GR; Ryecroft W; Matassa VG
    J Med Chem; 1996 Feb; 39(4):842-9. PubMed ID: 8632408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CCKB receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice.
    Hernando F; Fuentes JA; Roques BP; Ruiz-Gayo M
    Eur J Pharmacol; 1994 Aug; 261(3):257-63. PubMed ID: 7813546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists.
    Boden PR; Higginbottom M; Hill DR; Horwell DC; Hughes J; Rees DC; Roberts E; Singh L; Suman-Chauhan N; Woodruff GN
    J Med Chem; 1993 Mar; 36(5):552-65. PubMed ID: 7684452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.
    Ito H; Sogabe H; Nakarai T; Sato Y; Tomoi M; Kadowaki M; Matsuo M; Tokoro K; Yoshida K
    J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and morphine enhancement activity of N-[5-(2-phenoxyphenyl)-1, 3, 4-oxadiazole-2-yl]-N'-phenylurea derivatives.
    Rad AA; Sheikhha M; Hosseini R; Tabatabaic SA; Shafiee A
    Arch Pharm (Weinheim); 2004 Apr; 337(4):193-200. PubMed ID: 15065078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationally designed "dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties.
    Horwell DC; Hughes J; Hunter JC; Pritchard MC; Richardson RS; Roberts E; Woodruff GN
    J Med Chem; 1991 Jan; 34(1):404-14. PubMed ID: 1671419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus.
    Farook JM; Zhu YZ; Wang Q; Moochhala SM; Lee L; Wong PT
    Neurosci Lett; 2004 Apr; 358(3):215-9. PubMed ID: 15039119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand.
    Chang RS; Chen TB; Bock MG; Freidinger RM; Chen R; Rosegay A; Lotti VJ
    Mol Pharmacol; 1989 Jun; 35(6):803-8. PubMed ID: 2733696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cholecystokinin peptides and GV 150013, a selective cholecystokininB receptor antagonist, on electrically evoked endogenous GABA release from rat cortical slices.
    Ferraro L; Beani L; Trist D; Reggiani A; Bianchi C
    J Neurochem; 1999 Nov; 73(5):1973-81. PubMed ID: 10537055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression.
    Wesołowska A; Nikiforuk A
    Neuropharmacology; 2007 Apr; 52(5):1274-83. PubMed ID: 17320917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptoid CCK receptor antagonists: pharmacological evaluation of CCKA, CCKB and mixed CCKA/B receptor antagonists.
    Singh L; Field MJ; Hill DR; Horwell DC; McKnight AT; Roberts E; Tang KW; Woodruff GN
    Eur J Pharmacol; 1995 Nov; 286(2):185-91. PubMed ID: 8605955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
    Dawson LA; Hughes ZA; Starr KR; Storey JD; Bettelini L; Bacchi F; Arban R; Poffe A; Melotto S; Hagan JJ; Price GW
    Neuropharmacology; 2006 Jun; 50(8):975-83. PubMed ID: 16581092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.